Abstract
Muscimol, a constituent of the mushroomAmanita muscaria, is a semirigid analogue of the inhibitory neurotransmitter 4-aminobutyric acid (GABA). X-ray structure determinations and quantum chemicalab initio calculations (HF/6-31G*) have been carried out on the muscimol zwitterion. The solid-state conformations of the muscimol zwitterion are calculated to be 1.6–2.2 kcal/mol higher in energy than that of the calculated minimum energy structurein vacuo. A comparison of the calculated and experimental structures indicates that the hydrogen bonding network in the solid state significantly affects the geometry of the molecular structure. This conclusion is supported by results ofab initio calculations on binary complexes between muscimol and an ammonium ion and between muscimol and a methoxide anion, simulating observed hydrogen bonding in the crystal structures.
Similar content being viewed by others
References
Krujevic, K.Physiol. Rev. 1974,54, 418–540.
Olsen, R. W.; Venter, J. C.Benzodiazepine/GABA Receptors and Chloride Channels: Structural and Functional Properties; New York: Liss, 1986.
Barnard, E. A.; Costa, E.Allosteric Modulation of Amino Acid Receptors: Therapeutic Implication; New York: Raven Press, 1989.
Bowery, N. G.; Nistico, G.GABA: Basic Research and Clinical Applications; Rome: Pythagora Press, 1989.
Nistico, G.; Morselli, P. L.; Lloyd, K. G.; Fariello, R. G.; Engel, J.Neurotransmitters, Seizures, and Epilepsy III; New York: Raven Press, 1986.
Krogsgaard-Larsen, P.; FrØlund, B.; JØrgensen, F. S.; Schousboe, A.J. Med. Chem. 1994,37, 2489–2505.
Eugster, C. H.Fortschr. Chem. Org. Naturstoffe 1969,27, 261–321.
Krogsgaard-Larsen, P.; Brehm, L.; Schaumburg, K.Acta Chem. Scand. 1981,B35, 311–324.
Johnston, G. A. R.; Curtis, D. R.; De Groat, W. C.; Duggan, A. W.Biochem. Pharmacol. 1968,17, 2488–2489.
Krogsgaard-Larsen, P.; Johnston, G. A. R.; Curtis, D. R.; Game, C. J. A.; McCulloch, R. M.J. Neurochem. 1975,25, 803–809.
Krogsgaard-Larsen, P.; Falch, E.; Hjeds, H.Prog. Med. Chem. 1985,22, 67–120.
Bowden, K.; Crank, G.; Ross, W. J.J. Chem. Soc. C1968, 172–185.
Krogsgaard-Larsen, P.; Christensen, S. B.Acta Chem. Scand. 1976,B30, 281–282.
Chiarino, D.; Napoletano, M.; Sala, A.Tetrahedron Lett. 1986,27, 3181–3182.
Pevarello, P.; Varasi, M.Synth. Comm. 1992,22, 1939–1948, and references cited therein.
Krogsgaard-Larsen, P.; Hjeds, H.; Curtis, D. R.; Lodge, D.; Johnston, G. A. R. J.Neurochem. 1979,32, 1717–1724.
Fowler, L. J.; Lovell, D. H.; John, R. A.J. Neurochem. 1983,41, 1751–1754.
Krogsgaard-Larsen, P.Acta Chem. Scand. 1977,B31, 584–588.
Krogsgaard-Larsen, P.; Johnston, G. A. R.; Lodge, D.; Curtis, D. R.Nature 1977,268, 53–55.
Krogsgaard-Larsen, P.; Hjeds, H.; Falch, E.; JØrgensen, F. S.; Nielsen, L.Adv. Drug Res. 1988,17, 381–456.
Lykkeberg, J.; Krogsgaard-Larsen, P.Acta Chem. Scand. 1976,B30, 781–785.
Krogsgaard-Larsen, P.; Larsen, A. L. N.; Thyssen, K.Acta Chem. Scand. 1978,B32, 469–477.
Krogsgaard-Larsen, P.; Nielsen, L.; Falch, E.; Curtis, D. R.J. Med. Chem. 1986,28, 1612–1617.
Brehm, L.; Hjeds, H.; Krogsgaard-Larsen, P.Acta Chem. Scand. 1972,26, 1298–1299.
Blessing, R. H.Cryst. Rev. 1987,1, 3–58.
Blessing, R. H.J. Appl. Crystallogr. 1989,22, 396–397.
Sheldrick, G. M.Acta Crystallogr. 1990,A46, 467–473.
Sheldrick, G. M.SHELXL93. Program for the Refinement of Crystal Structures; Göttingen, Germany: University of Göttingen, 1993.
International Tables for Crystallography, Vol. C; Dordrecht: Kluwer, 1992, Tables 4.2.6.8 and 6.1.1.4.
Spartan SGI version 4.0.3 GL Wavefunction, Inc., 18401 von Karman, suite 370, Irvine, CA 92715.
Johnson, C. K., ORTEPII; Report ORNL-5138; Oak Ridge National Laboratory, Tennessee, 1976.
Allen, F. H.; Kennard, O.Chem. Design Automation News 1993,8, 31–37.
Brehm, L.; Krogsgaard-Larsen, P.; Hjeds, H.Acta Chem. Scand. 1974,B28, 308–316.
Brehm, L.; Krogsgaard-Larsen, P.Acta Chem. Scand. 1974,B28, 625–635.
Brehm, L.; Larsen, A. L. N.Acta Crystallogr. 1976,B32, 3336–3339.
Brehm, L.Acta Crystallogr. 1977,B33, 146–148.
Kier, L. B.; Truitt, E. B. Jr.Experientia 1970,26, 988–989.
Andrews, P. R.; Johnston, G. A. R.J. Theor. Biol. 1979,79, 263–273.
Lipkowitz, K. B.; Gilardi, R. D.; Aprison, M. H.J. Mol. Struct. 1989,195, 65–77.
Tsuda, M.Mie Med. J. 1992,42, 7–19.
Tsuda, M.; Takada, T.; Miyasaki, M.; Uda, Y.; Kuzuhara, S.; Kitaura, K.J. Mol. Struct. (Theochem) 1993,280, 261–272.
Boulanger, T.; Vercauteren, D. P.; Durant, F.; André, J.-M.Int. J. Quant. Chem. 1988,15, 149–165.
Armstrong, D. R.; Breckenridge, R. J.; Suckling, C. J.J. Theor. Biol. 1982,97, 267–276.
Boulanger, T.; Vercauteren, D. P.; Durant, F.; André, J.-M.J. Theor. Biol. 1987,127, 479–489.
Cioslowski, J.; Fleischmann, E. D.Croat. Chem. Acta 1993,66, 113–121.
Lipkowitz, K. B. Personal communication, 1996.
Stewart, J. J. P.Rev. Computational Chem. 1990,1, 45–81.
Krogsgaard-Larsen, P. InAmino Acids as Chemical Transmitters; Fonnum, F., ed.; New York: Plenum Press, 1978, pp. 305–321.
Norrby, P.-O.; Liljefors, T. Unpublished results calculated by using a newly developed MM3 parameter set for 3-isoxazolol; manuscript in preparation, 1997.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brehm, L., Frydenvang, K., Hansen, L.M. et al. Structural features of muscimol, a potent GABAA receptor agonist, crystal structure and quantum chemicalab initio calculations. Struct Chem 8, 443–451 (1997). https://doi.org/10.1007/BF02311703
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02311703